Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Welcome and Introduction to Vi3C

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Aug

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Welcome and Introduction to Vi3C

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Darovasertib Plus Crizotinib May Set New First-Line Standard in HLA-A2–Negative Metastatic Uveal Melanoma

AASLD Publishes Landmark North American Framework to Advance Treatment Decisions for HCC

AI Model Predicts TP53 Status Tumor Type and Survival From Routine HE Slides

Adding Irinotecan to Preoperative Chemoradiotherapy Does Not Improve Outcomes in Locally Advanced Rectal Cancer

Early Intravesical Pirarubicin Improves Relapse-Free Survival in Upper Tract Urothelial Carcinoma